Cargando…
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
BACKGROUND: Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2. METHODS: ATC were generated from PBMC activated for 14 days with anti-CD3 mono...
Autores principales: | Zitron, Ian M, Thakur, Archana, Norkina, Oxana, Barger, Geoffrey R, Lum, Lawrence G, Mittal, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599512/ https://www.ncbi.nlm.nih.gov/pubmed/23433400 http://dx.doi.org/10.1186/1471-2407-13-83 |
Ejemplares similares
-
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014) -
In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015) -
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021) -
Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022) -
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)